Comparison · Verified July 2026
Compounded vs brand-name GLP-1: the math changed in 2026
For two years the answer was obvious: compounded semaglutide cost a fraction of
Wegovy. That gap has largely closed. Manufacturer direct-to-consumer pricing now overlaps with
compounded telehealth — and most people haven't recalculated.
What changed
Brand GLP-1 makers launched direct-to-consumer pricing, and the TrumpRx platform (live since
February 2026) lists brand semaglutide in the low hundreds rather than the ~$1,349 list price.
Meanwhile the FDA resolved the semaglutide and tirzepatide shortages, which narrows the legal
runway for mass-market compounding. The old "compounded is 80% cheaper" rule of thumb is out of date.
Affiliate disclosure: Veritide earns a commission when readers start care through some provider links on this page, at no extra cost to you. Commissions never influence our scores or rankings — we do not sell placement. See our
full disclosure and
scoring methodology.
| Compounded (telehealth) | Brand, direct-to-consumer |
|---|
| FDA approval | Not approved as a finished product | FDA-approved |
| Typical semaglutide cost | $149–$299/mo | $149–$349/mo (direct programs) |
| Typical tirzepatide cost | $259–$549/mo | $299–$449/mo (direct programs) |
| Brand via a telehealth provider | — | $1,149–$1,999/mo (marked up) |
| Clinical trial evidence | Molecule yes; product no | Full trial program |
| Dose flexibility | Microdosing, custom titration | Fixed approved doses |
| Insurance | Never covered | Sometimes covered |
| Medicare (eligible seniors) | Not covered | $50/mo via GLP-1 Bridge |
Direct-program pricing varies by product, dose, and
eligibility, and changes frequently. Verify current pricing on the manufacturer's own platform
before committing. Compounded pricing verified July 2026.
The middleman markup nobody mentions
Several telehealth providers we review will happily sell you brand Wegovy or Zepbound — at
$1,149 to $1,999 per month. That is the same FDA-approved drug you may be able to get
from the manufacturer's own direct program for a fraction of the price. If you have decided you want
the brand product, the telehealth provider is usually the most expensive way to buy it.
The rule that actually holds in 2026
Want the
brand drug? Buy it direct from the manufacturer's program, not through a
telehealth reseller. Want
compounded? Buy from a flat-rate provider with a named
pharmacy. Never buy brand through a compounding-focused telehealth middleman.
On Medicare? The math changes again
The Medicare GLP-1 Bridge went live July 1, 2026: eligible Part D enrollees pay a flat
$50/month copay for covered brand GLP-1s through December 2027. If you qualify,
nothing in the compounded market comes close. See our
Medicare GLP-1 Bridge briefing.
When compounded still wins
- Microdosing and custom titration — brand comes in fixed approved doses.
- Formats the brand doesn't make — oral drops, sublingual, compounded blends.
- You don't qualify for a direct program or Medicare Bridge.
- Your dose genuinely prices lower compounded — run the numbers per dose.
FAQ
Is compounded semaglutide cheaper than brand-name in 2026?
Not automatically — and this is the biggest change in the category. Manufacturer direct-to-consumer programs and the TrumpRx platform have pushed brand semaglutide down to roughly $149–$349/mo and brand tirzepatide to roughly $299–$449/mo. That overlaps directly with compounded telehealth pricing. Price the brand direct programs before you assume compounded is cheaper.
Why do telehealth providers charge $1,999 for brand GLP-1?
Because they're reselling it. Several providers we review offer brand Wegovy or Zepbound at $1,149–$1,999/mo. If you want the brand drug, buying through the manufacturer's own direct-to-consumer program is generally far cheaper than buying the same drug through a telehealth middleman.
Is compounded semaglutide as good as Wegovy?
It uses the same active ingredient, and the molecule's evidence base (STEP-1: ~14.9% body weight loss over 68 weeks) is real. But a specific compounded finished product has not been through the trials the brand product has, and it is not FDA-approved. That gap is the trade-off you're accepting.
When does compounded still make sense?
When you need a dose the brand doesn't make (microdosing, non-standard titration), when you want a format the brand doesn't offer, when you don't qualify for a direct program, or when the compounded price genuinely beats the brand direct price for your dose. Do the math per dose, not per headline.
Affiliate disclosure: Veritide earns a commission when readers start care through some provider links on this page, at no extra cost to you. Commissions never influence our scores or rankings — we do not sell placement. See our
full disclosure and
scoring methodology.
Medical disclaimer: Veritide is an independent consumer-research publication, not a healthcare provider or pharmacy. This page is informational and is not medical advice. Compounded medications are not FDA-approved as finished products. Always consult a licensed clinician before starting any peptide or GLP-1 therapy.